Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging of Human Hair to Characterize Longitudinal Profiles of the Antiretroviral Maraviroc for Adherence Monitoring.

Gilliland WM Jr, Prince HMA, Poliseno A, Kashuba ADM, Rosen EP.

Anal Chem. 2019 Aug 20;91(16):10816-10822. doi: 10.1021/acs.analchem.9b02464. Epub 2019 Aug 6.

PMID:
31345022
2.

Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species.

Thompson CG, Rosen EP, Prince HMA, White N, Sykes C, de la Cruz G, Mathews M, Deleage C, Estes JD, Charlins P, Mulder LR, Kovarova M, Adamson L, Arora S, Dellon ES, Peery AF, Shaheen NJ, Gay C, Muddiman DC, Akkina R, Garcia JV, Luciw P, Kashuba ADM.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaap8758. doi: 10.1126/scitranslmed.aap8758.

PMID:
31270274
3.

Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Burgunder E, Fallon JK, White N, Schauer AP, Sykes C, Remling-Mulder L, Kovarova M, Adamson L, Luciw P, Garcia JV, Akkina R, Smith PC, Kashuba ADM.

J Pharmacol Exp Ther. 2019 Sep;370(3):360-368. doi: 10.1124/jpet.119.259150. Epub 2019 Jun 24.

PMID:
31235531
4.

HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Leibrand CR, Paris JJ, Jones AM, Masuda QN, Halquist MS, Kim WK, Knapp PE, Kashuba ADM, Hauser KF, McRae M.

J Neurovirol. 2019 May 17. doi: 10.1007/s13365-019-00757-8. [Epub ahead of print]

PMID:
31102185
5.

Using Real-Time Adherence Feedback to Enhance Communication About Adherence to Antiretroviral Therapy: Patient and Clinician Perspectives.

Hill LM, Golin CE, Pack A, Carda-Auten J, Wallace DD, Cherkur S, Farel CE, Rosen EP, Gandhi M, Asher Prince HM, Kashuba ADM.

J Assoc Nurses AIDS Care. 2019 Apr 26. doi: 10.1097/JNC.0000000000000089. [Epub ahead of print]

PMID:
31033629
6.

Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for HIV pre-exposure prophylaxis (PrEP).

Cottrell ML, Prince HMA, Schauer AP, Sykes C, Maffuid K, Poliseno A, Chun TW, Huiting E, Stanczyk FZ, Peery AF, Dellon ES, Adams JL, Gay C, Kashuba ADM.

Clin Infect Dis. 2019 Apr 9. pii: ciz290. doi: 10.1093/cid/ciz290. [Epub ahead of print]

PMID:
30963179
7.

Contemporary Drug-Drug Interactions in HIV Treatment.

Devanathan AS, Anderson DJC, Cottrell ML, Burgunder EM, Saunders AC, Kashuba ADM.

Clin Pharmacol Ther. 2019 Jun;105(6):1362-1377. doi: 10.1002/cpt.1393. Epub 2019 Mar 25.

PMID:
30739315
8.

Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.

Srinivas N, Joseph SB, Robertson K, Kincer LP, Menezes P, Adamson L, Schauer AP, Blake KH, White N, Sykes C, Luciw P, Eron JJ, Forrest A, Price RW, Spudich S, Swanstrom R, Kashuba ADM.

Clin Transl Sci. 2019 May;12(3):302-311. doi: 10.1111/cts.12620. Epub 2019 Feb 27.

9.

Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings.

Rudolph JE, Cole SR, Eron JJ, Kashuba AD, Adimora AA.

Epidemiology. 2019 May;30(3):358-364. doi: 10.1097/EDE.0000000000000966.

PMID:
30640216
10.

Patient and clinician perspectives on optimizing graphical displays of longitudinal medication adherence data.

Pack AP, Golin CE, Hill LM, Carda-Auten J, Wallace DD, Cherkur S, Farel CE, Rosen EP, Gandhi M, Asher Prince HM, Kashuba ADM.

Patient Educ Couns. 2019 Jun;102(6):1090-1097. doi: 10.1016/j.pec.2018.12.029. Epub 2019 Jan 2.

PMID:
30626550
11.

Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients.

Medina-Moreno S, Zapata JC, Cottrell ML, Le NM, Tao S, Bryant J, Sausville E, Schinazi RF, Kashuba AD, Redfield RR, Heredia A.

Antivir Ther. 2019;24(3):177-186. doi: 10.3851/IMP3285.

PMID:
30574873
12.

Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).

Imaz A, Niubó J, Cottrell ML, Perez E, Kashuba ADM, Tiraboschi JM, Morenilla S, Garcia B, Podzamczer D.

Clin Infect Dis. 2018 Dec 18. doi: 10.1093/cid/ciy1074. [Epub ahead of print]

PMID:
30561517
13.

Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.

Dumond JB, Greene SA, Prince HM, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JA, Gay CL, Kashuba AD, Cohen MS.

Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277.

PMID:
30375984
14.

Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species.

Srinivas N, Rosen EP, Gilliland WM Jr, Kovarova M, Remling-Mulder L, De La Cruz G, White N, Adamson L, Schauer AP, Sykes C, Luciw P, Garcia JV, Akkina R, Kashuba ADM.

Xenobiotica. 2019 Oct;49(10):1192-1201. doi: 10.1080/00498254.2018.1539278. Epub 2018 Dec 17.

PMID:
30346892
15.

Evaluation of Digital Image Recognition Methods for Mass Spectrometry Imaging Data Analysis.

Ekelöf M, Garrard KP, Judd R, Rosen EP, Xie DY, Kashuba ADM, Muddiman DC.

J Am Soc Mass Spectrom. 2018 Dec;29(12):2467-2470. doi: 10.1007/s13361-018-2073-0. Epub 2018 Oct 15.

PMID:
30324263
16.

Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.

Krovi SA, Gallovic MD, Keller AM, Bhat M, Tiet P, Chen N, Collier MA, Gurysh EG, Pino EN, Johnson MM, Shamim Hasan Zahid M, Cottrell ML, Pirone JR, Kashuba AD, Kwiek JJ, Bachelder EM, Ainslie KM.

Int J Pharm. 2018 Dec 1;552(1-2):371-377. doi: 10.1016/j.ijpharm.2018.10.017. Epub 2018 Oct 8.

17.

Ultra-long-acting removable drug delivery system for HIV treatment and prevention.

Kovarova M, Benhabbour SR, Massud I, Spagnuolo RA, Skinner B, Baker CE, Sykes C, Mollan KR, Kashuba ADM, García-Lerma JG, Mumper RJ, Garcia JV.

Nat Commun. 2018 Oct 8;9(1):4156. doi: 10.1038/s41467-018-06490-w.

18.

Development and validation of an LC-MS/MS assay for the quantification of dolutegravir extracted from human hair.

Sykes C, Blake K, White N, Schauer AP, Guzman BB, Cottrell ML, Tamraz B, Kashuba ADM.

Anal Bioanal Chem. 2018 Nov;410(29):7773-7781. doi: 10.1007/s00216-018-1394-y. Epub 2018 Oct 2.

PMID:
30280227
19.

Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users.

Thurman AR, Schwartz JL, Brache V, Chen BA, Chandra N, Kashuba ADM, Weiner DH, Mauck C, Doncel GF.

J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):79-88. doi: 10.1097/QAI.0000000000001864.

PMID:
30212395
20.

Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial.

Mitchell JT, LeGrand S, Hightow-Weidman LB, McKellar MS, Kashuba AD, Cottrell M, McLaurin T, Satapathy G, McClernon FJ.

JMIR Mhealth Uhealth. 2018 Sep 10;6(9):e10456. doi: 10.2196/10456.

21.

Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques.

Brocca-Cofano E, Xu C, Wetzel KS, Cottrell ML, Policicchio BB, Raehtz KD, Ma D, Dunsmore T, Haret-Richter GS, Musaitif K, Keele BF, Kashuba AD, Collman RG, Pandrea I, Apetrei C.

J Virol. 2018 Aug 16;92(17). pii: e00576-18. doi: 10.1128/JVI.00576-18. Print 2018 Sep 1.

22.

Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.

Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD, Dellon ES, De Paris K, Nelson JA, Gay CL, Kashuba AD.

Antivir Ther. 2018;23(6):495-504. doi: 10.3851/IMP3236.

PMID:
29714167
23.

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.

McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivro A, Nagelkerke N, Garcia Lerma JG, Kashuba AD, Masson L, Mansoor LE, Karim QA, Karim SSA, Passmore JS.

Nat Med. 2018 May;24(4):491-496. doi: 10.1038/nm.4506. Epub 2018 Feb 26.

24.

Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Srinivas N, Maffuid K, Kashuba ADM.

Clin Pharmacokinet. 2018 Sep;57(9):1059-1074. doi: 10.1007/s40262-018-0632-y. Review.

PMID:
29464550
25.

Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.

Shen Z, Rodriguez-Garcia M, Patel MV, Bodwell J, Kashuba ADM, Wira CR.

Sci Rep. 2017 Dec 18;7(1):17697. doi: 10.1038/s41598-017-18078-3.

26.

The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue.

Nicol MR, Brewers LM, Kashuba ADM, Sykes C.

AIDS. 2018 Jan 2;32(1):11-15. doi: 10.1097/QAD.0000000000001678.

PMID:
29112071
27.

Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.

Schauer AP, Sykes C, Cottrell ML, Prince H, Kashuba ADM.

J Pharm Biomed Anal. 2018 Feb 5;149:40-45. doi: 10.1016/j.jpba.2017.10.030. Epub 2017 Oct 31.

28.

Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.

Asmuth DM, Thompson CG, Chun TW, Ma ZM, Mann S, Sainz T, Serrano-Villar S, Utay NS, Garcia JC, Troia-Cancio P, Pollard RB, Miller CJ, Landay A, Kashuba AD.

J Infect Dis. 2017 Oct 17;216(7):813-818. doi: 10.1093/infdis/jix418.

29.

Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.

Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, Lee CR, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell JR.

Clin Transl Sci. 2017 Nov;10(6):443-454. doi: 10.1111/cts.12490. Epub 2017 Aug 10. Review. No abstract available.

30.

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD, Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM.

J Clin Invest. 2017 Aug 1;127(8):3126-3135. doi: 10.1172/JCI92684. Epub 2017 Jul 17.

31.

Multimodal analysis of drug transporter expression in gastrointestinal tissue.

Thompson CG, Fallon JK, Mathews M, Charlins P, Remling-Mulder L, Kovarova M, Adamson L, Srinivas N, Schauer A, Sykes C, Luciw P, Garcia JV, Akkina R, Smith PC, Kashuba ADM.

AIDS. 2017 Jul 31;31(12):1669-1678. doi: 10.1097/QAD.0000000000001554.

32.

A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.

Feder AF, Kline C, Polacino P, Cottrell M, Kashuba ADM, Keele BF, Hu SL, Petrov DA, Pennings PS, Ambrose Z.

PLoS Pathog. 2017 May 25;13(5):e1006358. doi: 10.1371/journal.ppat.1006358. eCollection 2017 May.

33.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

PLoS Pathog. 2017 May 3;13(5):e1006368. doi: 10.1371/journal.ppat.1006368. eCollection 2017 May.

34.

HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Thompson CG, Gay CL, Kashuba ADM.

AIDS Res Hum Retroviruses. 2017 Jun;33(6):513-523. doi: 10.1089/AID.2016.0253. Epub 2017 May 16. Review.

35.

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.

Cottrell ML, Garrett KL, Prince HMA, Sykes C, Schauer A, Emerson CW, Peery A, Rooney JF, McCallister S, Gay C, Kashuba ADM.

J Antimicrob Chemother. 2017 Jun 1;72(6):1731-1740. doi: 10.1093/jac/dkx064.

36.

Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.

Wahl A, Ho PT, Denton PW, Garrett KL, Hudgens MG, Swartz G, O'Neill C, Veronese F, Kashuba AD, Garcia JV.

Sci Rep. 2017 Feb 1;7:41098. doi: 10.1038/srep41098.

37.

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

Imaz A, Martinez-Picado J, Niubó J, Kashuba AD, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczer D.

J Infect Dis. 2016 Nov 15;214(10):1512-1519. Epub 2016 Aug 30.

38.

Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers.

Asher GN, Xie Y, Moaddel R, Sanghvi M, Dossou KS, Kashuba AD, Sandler RS, Hawke RL.

J Clin Pharmacol. 2017 Feb;57(2):185-193. doi: 10.1002/jcph.806. Epub 2016 Sep 6.

39.

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.

Khandelwal P, Fukuda T, Mizuno K, Teusink-Cross A, Mehta PA, Marsh RA, Kashuba ADM, Vinks AA, Davies SM.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1829-1835. doi: 10.1016/j.bbmt.2016.08.001. Epub 2016 Aug 3.

40.

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

Imaz A, Niubó J, Kashuba AD, Ferrer E, Sykes C, Rozas N, Acerete L, Vila A, Podzamczer D.

HIV Med. 2017 Mar;18(3):225-230. doi: 10.1111/hiv.12417. Epub 2016 Aug 1.

41.

Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.

Slaven JE, Decker BS, Kashuba ADM, Atta MG, Wyatt CM, Gupta SK.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):e8-e10. doi: 10.1097/QAI.0000000000001106. No abstract available.

42.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

PLoS Pathog. 2016 Mar 25;12(3):e1005540. doi: 10.1371/journal.ppat.1005540. eCollection 2016 Mar. No abstract available.

43.

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, Kashuba AD.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):498-506. doi: 10.1097/QAI.0000000000000996.

44.

Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.

Oramasionwu CU, Kashuba AD, Napravnik S, Wohl DA, Mao L, Adimora AA.

World J Hepatol. 2016 Mar 8;8(7):368-75. doi: 10.4254/wjh.v8.i7.368.

45.

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD.

J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.

46.

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.

Chang AT, Bertino JS Jr, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma JD.

Ther Drug Monit. 2016 Jun;38(3):383-7. doi: 10.1097/FTD.0000000000000277.

PMID:
26818625
47.

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

PLoS Pathog. 2016 Jan 21;12(1):e1005381. doi: 10.1371/journal.ppat.1005381. eCollection 2016 Jan. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005540. Wook-Chun, Tae [corrected to Chun, Tae-Wook]. Erratum in: PLoS Pathog. 2017 May 3;13(5):e1006368.

48.

Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.

Veselinovic M, Yang KH, Sykes C, Remling-Mulder L, Kashuba AD, Akkina R.

Virology. 2016 Feb;489:173-8. doi: 10.1016/j.virol.2015.12.014. Epub 2016 Jan 6.

49.

Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging.

Rosen EP, Thompson CG, Bokhart MT, Prince HM, Sykes C, Muddiman DC, Kashuba AD.

Anal Chem. 2016 Jan 19;88(2):1336-44. doi: 10.1021/acs.analchem.5b03794. Epub 2015 Dec 30.

50.

Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.

Melody K, McBeth S, Kline C, Kashuba AD, Mellors JW, Ambrose Z.

Antimicrob Agents Chemother. 2015 Dec;59(12):7762-70. doi: 10.1128/AAC.01937-15. Epub 2015 Oct 5.

Supplemental Content

Loading ...
Support Center